EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

A Multimethod Evaluation to Assess Feasibility, Acceptability, and Preliminary Efficacy of HPVVaxFacts, a Tailored Mobile Web App, for Parents With Unvaccinated Children: Pilot 2-Arm Randomized Controlled Trial

Eine multimethodische Evaluation zur Machbarkeit, Akzeptanz und vorläufigen Wirksamkeit von HPVVaxFacts, einer angepassten mobilen Web-App, für Eltern mit ungeimpften Kindern: Pilot-RCT mit 2 Armen

Jennifer Cunningham-Erves iD, Pamela C Hull iD, Amanda F Dempsey iD, Tatsuki Koyama iD, Lili Sun iD, Mariya Chalise iD, Elizabeth C Stewart iD, Jessica L Jones iD, Douglas Landsittel iD, Meredith Smalls iD, Freneka F Minter iD, Lindsay S Mayberry iD und 6 weitere

JMIR Cancer · 09.09.2026 · 12 · e78910-e78910

DOI: 10.2196/78910 ↗

Auf einen Blick

In einer Pilotstudie mit 57 Eltern war HPVVaxFacts machbar und akzeptabel. Die Impfinitiierung war nach 12 Monaten in der Interventionsgruppe höher als in der Kontrollgruppe.

Fragestellung

Wie machbar, akzeptabel und vorläufig wirksam ist HPVVaxFacts bei Eltern von 9- bis 17-jährigen ungeimpften Jugendlichen?

Methode

Pilot-RCT in 2 urbanen Kliniken in Tennessee; HPVVaxFacts gegen Ernährungsinformation als Attention Control; Erhebung per Surveys, Interviews und EHR.

Ergebnisse

57 eingeschlossene Eltern; 81 % sahen HPVVaxFacts. Impfinitiierung: 48 % vs. 17 %; Differenz 0,24; 95 %-KI 0,03–0,46; P=.01. Wissens- und Sorgenänderungen waren zwischen den Gruppen nicht signifikant.

Einschränkungen

Nicht verblindet für Eltern; kleine Pilotstudie; nur englischsprachige Inhalte; digitale Form als Barriere.

Schlussfolgerung der Autor:innen

Die Studie deutet darauf hin, dass HPVVaxFacts bei Eltern machbar und akzeptabel ist, um vor dem Besuch personalisierte Infos zur HPV-Impfung bereitzustellen. Weitere Wirksamkeitsprüfung ist nötig.

Kernaussagen

  • HPVVaxFacts war in der Pilotstudie machbar und akzeptabel.
  • Impfinitiierung nach 12 Monaten: 48 % vs. 17 %.
  • Wissens- und Sorgenwerte verbesserten sich, aber nicht signifikant.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JMIR Cancer, online erschienen am 09.09.2026. Verfasst von Jennifer Cunningham-Erves und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Policy, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 700, Nashville, TN, United States, 615-541-9375. Hauptthemen laut MEDLINE: Parents, Papillomavirus Infections, Mobile Applications, Papillomavirus Vaccines. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mobile health (mHealth) interventions may improve provider-parent communication on human papillomavirus (HPV) vaccination to reduce concerns, and increase intention and uptake. HPVVaxFacts (233 Analytics) is a novel, mobile web app delivering tailored education based on the Health Belief Model and Theory of Reasoned Action, addressing parental concerns preclinic visit.

Objective

This study aimed to assess the feasibility, acceptability, and preliminary efficacy of HPVVaxFacts among parents of adolescents aged 9‐17 years.

Methods

We conducted a pilot, randomized controlled trial in 2 urban Tennessee clinics from June to September 2023 comparing 2 groups: tailored education via HPVVaxFacts mobile web app (intervention, n=27), and nutrition education (attention control, n=30). Eligible parents had or were caregivers to a child aged 9 to 17 years unvaccinated against HPV, had a mobile phone, had an upcoming clinic visit, and spoke English. The recruitment strategy was patient intake software—Phreesia (Phreesia, Inc ) and eClinicalWorks (eClinicalWorks). Although unblinded, parents could deduce their study arm assignment. Providers were blinded. Feasibility, acceptability, and preliminary efficacy (HPV vaccine knowledge, concerns, intentions, and vaccination rates) were assessed using multimethod evaluation. Parents were assessed at baseline and immediately post intervention via surveys. Vaccination rates were assessed at 12 months post intervention via electronic health records. Nineteen parent interviews were conducted up to 9 months post intervention. A clinic staff consultation (n=6) was 1 month post intervention.

Results

Of 57 enrolled parents, most were female (52/57, 91%), non-Hispanic White (44/57, 77%), had ≤US $80,000 household income (32/57, 56%), and had some college or less (27/57, 47%). In total, 81% (36) of parents viewed HPVVaxFacts. Post intervention, HPV vaccine initiation was higher in the intervention group compared to the attention control group (48% vs 17%; difference 0.24; 95% CI 0.03-0.46; P =.01). Parents in the HPVVaxFacts arm demonstrated a greater reduction in knowledge (ie, knowledge increase; mean change: −0.6 vs 0.1) and concern scores (mean change: −3.4 vs −1.4) than those in the nutrition education arm. However, between-arm differences were not statistically significant ( P =.13 and P =.14, respectively). The majority found the study protocol and HPVVaxFacts acceptable. Benefits of HPVVaxFacts include confirming their decision to vaccinate, supporting parent-child discussion on the vaccine, and answering questions preclinic visit or offering questions for the provider. Study protocol delivery and mobile web app instructions were suggested areas for improvement. Barriers for HPVVaxFacts use include content in English only and digital format.

Conclusions

Our study suggests HPVVaxFacts was feasible and acceptable among parents to provide previsit, tailored information on HPV vaccination. Outcomes offer a positive trajectory but need more exploration. Next steps include a well-powered efficacy trial to determine the impact of HPVVaxFacts on initiation vaccine rates and parental hesitancy factors, as well as to explore an interaction, effect modification, and mediation among different variables.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ParentsPapillomavirus InfectionsMobile ApplicationsPapillomavirus VaccinesPatient Acceptance of Health CareVaccinationHumansFemaleChildMaleAdolescentPilot ProjectsFeasibility StudiesUnvaccinated PersonsAdultHuman Papillomavirus VirusesHealth Knowledge, Attitudes, PracticeTennessee

Stichwörter der Autor:innen

HPVchildren and adolescentsdigital interventionhuman papillomavirusmHealthmobile healthparentsvaccine uptake

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Department of Health Policy, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 700, Nashville, TN, United States, 615-541-9375.
  • Behavioral Science Department, University of Kentucky, Lexington, KY, United States.
  • MERCK, Rahway, NJ, United States.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States.
  • Graduate School of Public Health Practice, Meharry Medical College, Nashville, TN, United States.
  • Meharry-Vanderbilt Alliance, Nashville, TN, United States.

ORCID-Profile: Jennifer Cunningham-Erves, Pamela C Hull, Amanda F Dempsey, Tatsuki Koyama, Lili Sun, Mariya Chalise, Elizabeth C Stewart, Jessica L Jones, Douglas Landsittel, Meredith Smalls, Freneka F Minter, Lindsay S Mayberry, Lora Harnack, Michael J Hook, Janet Cates, Tammy Van Maanen, Taylor Burnett, Consuelo H Wilkins

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Cunningham-Erves, J., Hull, P. C., Dempsey, A. F., Koyama, T., Sun, L., Chalise, M., Stewart, E. C., Jones, J. L., Landsittel, D., Smalls, M., Minter, F. F., Mayberry, L. S., Harnack, L., Hook, M. J., Cates, J., Van Maanen, T., Burnett, T., & Wilkins, C. H. (2026). A Multimethod Evaluation to Assess Feasibility, Acceptability, and Preliminary Efficacy of HPVVaxFacts, a Tailored Mobile Web App, for Parents With Unvaccinated Children: Pilot 2-Arm Randomized Controlled Trial. JMIR Cancer, 12, e78910-e78910. https://doi.org/10.2196/78910

Vancouver

Cunningham-Erves J, Hull PC, Dempsey AF, Koyama T, Sun L, Chalise M, et al. A Multimethod Evaluation to Assess Feasibility, Acceptability, and Preliminary Efficacy of HPVVaxFacts, a Tailored Mobile Web App, for Parents With Unvaccinated Children: Pilot 2-Arm Randomized Controlled Trial. JMIR Cancer. 2026;12:e78910-e78910. doi:10.2196/78910

BibTeX
@article{CunninghamErves2026,
  author = {Cunningham-Erves, Jennifer and Hull, Pamela C and Dempsey, Amanda F and Koyama, Tatsuki and Sun, Lili and Chalise, Mariya and Stewart, Elizabeth C and Jones, Jessica L and Landsittel, Douglas and Smalls, Meredith and Minter, Freneka F and Mayberry, Lindsay S and Harnack, Lora and Hook, Michael J and Cates, Janet and Van Maanen, Tammy and Burnett, Taylor and Wilkins, Consuelo H},
  title = {A Multimethod Evaluation to Assess Feasibility, Acceptability, and Preliminary Efficacy of HPVVaxFacts, a Tailored Mobile Web App, for Parents With Unvaccinated Children: Pilot 2-Arm Randomized Controlled Trial},
  journal = {JMIR Cancer},
  year = {2026},
  volume = {12},
  pages = {e78910--e78910},
  doi = {10.2196/78910}
}
Kostenlos starten →